Valuation : Astellas Pharma Inc.

Market Cap 3,993B 25.84B 22.27B 21.02B 19.14B 35.75B 2,468B 36.13B 249B 96.15B 1,257B 97.12B 94.99B P/E 2027 *
10.7x
P/E 2028 * 11.4x
Enterprise Value 3,934B 25.46B 21.94B 20.71B 18.86B 35.22B 2,432B 35.59B 245B 94.73B 1,239B 95.68B 93.58B EV / Sales 2027 *
1.69x
EV / Sales 2028 * 1.63x
Free-Float
98.88%
Yield 2027 *
3.61%
Yield 2028 * 3.74%
1 day-1.65%
1 week-6.30%
Current month-4.03%
1 month-4.03%
3 months+7.21%
6 months-8.43%
Current year+6.92%
1 week 11.9
Extreme 11.9
12.9
1 month 11.9
Extreme 11.9
13.3
Current year 11
Extreme 11
14.19
1 year 8.56
Extreme 8.56
14.19
3 years 7.53
Extreme 7.534
14.19
5 years 7.53
Extreme 7.534
16
10 years 7.53
Extreme 7.534
16.7
Manager TitleAgeSince
Chief Executive Officer 64 2023-02-09
Director of Finance/CFO 54 2023-10-31
Compliance Officer - 2025-03-31
Director TitleAgeSince
Chairman 66 2023-02-09
Director/Board Member 64 2019-05-31
Director/Board Member 59 2023-05-31
Change 5-day change 1-year change 3-year change Capi.($)
-1.65%-6.30% - - 26.12B
-0.11%-3.20%+49.61%+91.49% 1,002B
-0.27%-3.22%+50.51%+65.89% 644B
+1.63%-2.57%+21.19%+71.12% 443B
-0.63%-1.06%+28.11%+34.59% 343B
+0.43%-14.61%+9.88%+27.26% 262B
+0.93%-1.82%-1.82%+8.41% 245B
-2.25%-13.63%+36.61%+47.43% 212B
-0.90%-5.09%-15.47%-57.75% 199B
-0.58%-3.21%+25.10%+90.54% 181B
Average +0.04%-5.00%+22.63%+42.11% 392.19B
Weighted average by Cap. +0.42%-4.24%+31.90%+57.11%

Financials

2027 *2028 *
Net sales 2,329B 15.07B 12.99B 12.26B 11.16B 20.85B 1,440B 21.07B 145B 56.08B 733B 56.65B 55.4B 2,155B 13.95B 12.02B 11.35B 10.33B 19.3B 1,332B 19.5B 134B 51.9B 679B 52.42B 51.27B
Net income 356B 2.3B 1.98B 1.87B 1.71B 3.19B 220B 3.22B 22.14B 8.57B 112B 8.65B 8.46B 333B 2.15B 1.85B 1.75B 1.59B 2.98B 206B 3.01B 20.7B 8.01B 105B 8.09B 7.91B
Net Debt -59.18B -383M -330M -312M -284M -530M -36.58B -535M -3.68B -1.43B -18.64B -1.44B -1.41B -481B -3.11B -2.68B -2.53B -2.3B -4.3B -297B -4.35B -29.92B -11.57B -151B -11.69B -11.43B
Logo Astellas Pharma Inc.
Astellas Pharma Inc is a Japan-based company mainly engaged in the research, development, manufacture and sales of pharmaceutical products. The Company mainly operates Pharmaceutical Products business segment. The main products include XTANDI, BETANIS, MIRABETRIC, BETMIGA and new products ZOSPATA, EVERENZO and ENHOLTUMAB VEDOTIN, among others.
Employees
14,099
Date Price Change Volume
26-09-10 €12.10 0.00% 0
26-09-09 €12.10 -1.63% 0
26-09-08 €12.30 -2.38% 0
26-09-07 €12.60 -2.33% 0
26-09-04 €12.90 -2.27% 0
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
2,227.00JPY
Average target price
2,512.14JPY
Spread / Average Target
+12.80%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!